Key result
Axitinib reduces cardiac fibrosis and improves pressure overload-induced dysfunction in mice via the VEGFA-KDR pathway.
Why the study?
No specific clinical medications target cardiac fibrosis in heart failure, and research on applying tyrosine kinase inhibitors to cardiac fibrosis is limited.
Does axitinib reduce cardiac fibrosis and improve cardiac function in pressure overload-induced heart failure models?
Does axitinib reduce cardiac fibrosis and improve cardiac function in pressure overload-induced heart failure models?
Axitinib demonstrates anti-fibrotic effects and improves cardiac function in a preclinical model of pressure overload-induced heart failure, suggesting potential for drug repurposing.
Answers are grounded in this paper and cite their sources.
Axitinib effects in mice do not support clinical use in HF; leaves open human trials of VEGFA-KDR targeting.
Background There are no specific clinical medications that target cardiac fibrosis in heart failure (HF). Recent studies have shown that tyrosine kinase inhibitors (TKIs) may benefit fibrosis in various organs. However, there is limited research on their application in cardiac fibrosis. Axitinib, an FDA-approved tyrosine kinase inhibitor, was used to evaluate its effects on cardiac fibrosis and function in pressure overload-induced heart failure. Methods To build a pharmacological network, the pharmacological targets of axitinib were first retrieved from databases and coupled with key heart failure gene molecules for analysis and prediction. To validate the results outlined above, 8-week-old male C57BL/6 J mice were orally administrated of axitinib (30 mg/kg) daily for 8 weeks after Transverse Aortic Constriction (TAC) surgery. Mouse cardiomyocytes and cardiac fibroblasts were used as cell lines to test the function and mechanism of axitinib. Results We found that the pharmacological targets of axitinib could form a pharmacological network with key genes involved in heart failure. The VEGFA-KDR pathway was found to be closely related to the differential gene expression of human heart-derived primary cardiomyocyte cell lines treated with axitinib, based on analysis of the publicly available dataset. The outcomes of animal experiments demonstrated that axitinib therapy greatly reduced cardiac fibrosis and improved TAC-induced cardiac dysfunction. Further research has shown that the expression of transforming growth factor-β(TGF-β) and other fibrosis genes was significantly reduced in vivo and in vitro . Conclusion Our study provides evidence for the repurposing of axitinib to combat cardiac fibrosis, and offers new insights into the treatment of patients with HF.
No takes yet. Share an insight, caveat, or question.
Jiao et al. (2023) studied Pressure overload-induced heart failure. Axitinib vs. Vehicle (Carboxymethylcellulose sodium) was evaluated on Cardiac fibrosis and TAC-induced cardiac dysfunction (p=<0.05). Axitinib therapy significantly reduced cardiac fibrosis and improved pressure overload-induced cardiac dysfunction in mice by modulating the VEGFA-KDR pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: